Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
798 Real-world overall survival among patients receiving first-line (1L) pembrolizumab in the treatment of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the United States
Compose a Response to This Article
Other responses
No responses have been published for this article.